GF CSI Innovative Drugs Industry ETF (515120) Rises 0.49% Against Market Trend; Multiple Biomedical Companies Post Strong Earnings Performance

NewTimeSpace News - As of 09:54 on March 30, 2026, the GF Securities Innovative Medicine ETF (515120) rose 0.49%, with its latest price reaching 0.61 yuan. Looking at a longer timeframe, as of March 27, 2026, the ETF has accumulated a gain of 3.05% over the past week. (The stocks listed above are solely index constituents and do not constitute specific investment recommendations.)

In terms of liquidity, the GF Securities Innovative Medicine ETF recorded an intraday turnover rate of 1.79% and a trading volume of 158 million yuan. Looking at a longer timeframe, as of March 27, the ETF's average daily trading volume reached 306 million yuan over the past week, ranking among the top 2 comparable funds.

Regarding fund size, the GF Securities Innovative Medicine ETF has grown by 459 million yuan over the past week, representing a significant increase and ranking 2nd among 7 comparable funds in terms of new asset inflows. (Data source: Wind)

In terms of fund shares, the GF Securities Innovative Medicine ETF increased by 64 million shares this month, achieving substantial growth and ranking 2nd among 7 comparable funds in terms of new share additions. (Data source: Wind)

For capital flows, the GF Securities Innovative Medicine ETF recorded a net outflow of 90.6999 million yuan in the latest session. Looking at a longer timeframe, over the past 20 trading days, 11 days saw net inflows, with a total of 39.6153 million yuan attracted, representing an average daily net inflow of 1.9808 million yuan. (Data source: Wind)

Data indicates continued positioning by leveraged funds. The GF Securities Innovative Medicine ETF recorded a margin purchase of 30.0248 million yuan in the latest session, with its latest margin balance reaching 304 million yuan. (Data source: Wind)

As of March 27, the GF Securities Innovative Medicine ETF has gained 17.62% over the past 2 years. In terms of return capability, as of March 27, 2026, since its inception, the ETF has achieved a maximum monthly return of 23.00%, a maximum consecutive rising period of 5 months, a maximum consecutive gain of 32.68%, and an average monthly return of 5.63% during rising months. As of March 27, 2026, the GF Securities Innovative Medicine ETF has outperformed its benchmark by 0.84% in annualized returns over the past 2 years.

Regarding drawdown, as of March 27, 2026, the GF Securities Innovative Medicine ETF's relative benchmark drawdown this year was 0.10%.

In terms of fee structure, the GF Securities Innovative Medicine ETF charges a management fee of 0.50% and a custody fee of 0.10%.

For tracking accuracy, as of March 27, 2026, the GF Securities Innovative Medicine ETF's tracking error over the past 5 years was 0.024%, achieving the highest tracking precision among comparable funds.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by the ETF currently has a price-to-earnings ratio (PE-TTM) of only 43.48x, standing at the 4.18th percentile over the past year, meaning the valuation is lower than 95.82% of the time during the past year, indicating a historically low level.

The GF Securities Innovative Medicine ETF closely tracks the CSI Innovative Medicine Industry Index, which selects up to 50 most representative listed companies from among those whose main business involves innovative drug research and development as index constituents to reflect the overall performance of innovative medicine industry listed companies.

Bohai Securities stated that this week, multiple biomedical companies disclosed annual reports, with several innovative drug and CXO companies posting standout performances. Some innovative drug companies achieved profitability turnarounds, with commercialization space continuously being realized and BD becoming a new growth pole. Domestic CRO companies are experiencing upward momentum, expected to see rising prices and volumes that will boost earnings performance. Leading CDMO companies show strong order books on hand, with new molecular types contributing new opportunities and high long-term earnings visibility.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.